Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Crisis Triage Rating Scale (CTRS) assessment

AM Alejandro Molina-López
JC Jeremy Bernardo Cruz-Islas
MP Mauricio Palma-Cortés
DG Diana Patricia Guizar-Sánchez
CG César Yehú Garfias-Rau
MO Martha Patricia Ontiveros-Uribe
AF Ana Fresán-Orellana
request Request a Protocol
ask Ask a question
Favorite

Certain randomly selected patients were further assessed with a simultaneous Spanish CTRS22 consisting of three domain scales: dangerousness, social support and cooperativeness assessment. The CTRS22 has been shown to help predict whether to admit or discharge a patient from the ED before a formal consultation. Each CTRS22 domain assessment consists of 5 conditions, hierarchically ordered from 1 (most severe condition) to 5 (least severe condition). Therefore, the lower the score, the higher the need to admit. Each CTRS22 domain has a maximum 5-point score, while the global CTRS score ranges from 3 to 15.

Copyright and License information: Molina-López et al. ©2016
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A